| 存储条件 |
|---|
| Product Name | UFD1L [F3-A6] |
|---|---|
| Antibody Type | Primary Antibodies |
| Antigen Alias | UB fusion protein 1 antibody Ubiquitin fusion degradation 1 like (yeast) antibody Ubiquitin fusion degradation 1 like antibody Ubiquitin fusion degradation protein 1 homolog antibody UFD1 antibody UFD1_HUMAN antibody UFD1L antibody |
| Product description | Ubiquitin-mediated proteolysis requires the transfer of ubiquitin (Ub) to lysine groups on selected cellular proteins, which then potentiates the proteolytic degradation of these protein conjugates by the 26S proteasome. Ub-fusions are cleaved by Ub-specific processing proteases (UBps) or alternatively by the Ub-fusion degradation (UFD) pathway. The UBP pathway targets the C-terminal glycine residue on Ub that is involved in the formation of Ub-conjugates, while UFD proteins preferentially cleave Ub-conjugated proteins that contain an amino acid substitution at this glycine residue. The UFD1 protein was originally characterized in the yeast S. cerevisiae and subsequently, the human homolog UFD1 or UFD1L was identified. In vitro, UFD1 attenuates the degradation of Ub-fusions, which have a proline or valine residue substituted at the Gly76 moiety, by the selective multiubiquitination of the Ub chain of the Ub-conjugate. Mutations within the UFD1 gene are implicated in the development of CATCH22 syndrome, which is characterized by cardiac defects, cleft palate and hypocalcemia, suggesting that this proteolytic pathway may be involved in the progression of these developmental defects. |
| Immunogen | Recombinant protein |
| Clonality | Monoclonal |
|---|---|
| Isotype | IgG2b |
| Host Species | Mouse |
| Tested Applications | WBICCIHCFC |
| WB:1:500-1:2,000 ICC:1:50-1:200 IHC:1:50-1:200 FC:1:50-1:200 | |
| Species Reactivity | Human |
| Concentration | 2mg/ml |
| Alternative Names | UB fusion protein 1 antibody Ubiquitin fusion degradation 1 like (yeast) antibody Ubiquitin fusion degradation 1 like antibody Ubiquitin fusion degradation protein 1 homolog antibody UFD1 antibody UFD1_HUMAN antibody UFD1L antibody |
|---|---|
| Cellular Localization | Nucleus. Cytoplasm?. |
| SwissProt ID | Q92890 |
|---|
Application
Fig1: Western blot analysis of UFD1L on human UFD1L recombinant protein using anti-UFD1L antibody at 1/1,000 dilution.
Application
Fig2: Western blot analysis of UFD1L on HEK293 (1) and UFD1L-hIgGFc transfected HEK293 (2) cell lysate using anti-UFD1L antibody at 1/1,000 dilution.
Application
Fig3: Western blot analysis of UFD1L on different cell lysate using anti-UFD1L antibody at 1/1,000 dilution. Positive control： Lane1: K562 Lane2: Hela Lane3: A431 Lane4: PC-2 Lane5: A549
Application
Fig4:ICC staining UFD1L (green) and Actin filaments (red) in Hela cells. The nuclear counter stain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilised with 0.25% Triton X100/PBS.
Application
Fig5: Immunohistochemical analysis of paraffin-embedded human esophageal cancer tissue using anti-UFD1L antibody. Counter stained with hematoxylin.
Application
Fig6: Immunohistochemical analysis of paraffin-embedded human endometrial cancer tissue using anti-UFD1L antibody. Counter stained with hematoxylin.
Application
Fig7:Flow cytometric analysis of Hela cells with UFD1L antibody at 1/100 dilution (green) compared with an unlabelled control (cells without incubation with primary antibody; red).| Positive Control | Human UFD1L recombinant protein, UFD1L-hIgGFc transfected HEK293 cell lysate, K562, Hela, A431, PC-2, A549, human endometrial cancer tissue, human esophageal cancer tissue. |
|---|---|
| Application Notes | WB:1:500-1:2,000 ICC:1:50-1:200 IHC:1:50-1:200 FC:1:50-1:200 |
| Form | Liquid |
|---|---|
| Storage Instructions | Store at +4℃ after thawing. Aliquot store at -20℃ or -80℃. Avoid repeated freeze / thaw cycles. |
| Storage Buffer | 1*TBS (pH7.4), 1%BSA, 40%Glycerol. Preservative: 0.05% Sodium Azide. |
抱歉，暂无相关文献
抱歉，暂无浏览记录
